Overcoming recurrence risk: Extended adjuvant endocrine therapy

Clinical Breast Cancer

Volumn 8, Issue 6, 2008, Pages 493-500

  Cianfrocca, Mary ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aminoglutethimide; Exemestane; Letrozole; Quality of Life; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ALOPECIA; ANOREXIA; ARTHRALGIA; BONE DENSITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FOLLOW UP; FRACTURE; HAZARD RATIO; HEALTH CARE COST; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; LYMPH NODE; METASTASIS; MYALGIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; POSTMENOPAUSE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; LYMPH NODE METASTASIS; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 60549102942     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.059     Document Type: Review

References (46)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
2. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-29.
3. Carlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4(suppl 1):S1-26.
4. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14:2738-46.
5. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:684-90.
6. Kennecke HF, Olivotto IA, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007; 18:45-51.
7. Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004; 22:1630-7.
8. Hortobagyi GN, Kau S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? Proc Am Soc Clin Oncol 2004; 22(14 suppl):23 (Abstract 585).
9. Peto R, Davies C on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women - preliminary results. Breast Cancer Res Treat 2007; 106(suppl 1): (Abstract 48).
10. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21:2101-9.
11. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-16.
12. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-802.
13. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 2004; 11:217-21.
14. Pater J, Tu D, Shepherd L, et al. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2008; 108:265-9.
15. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-71.
16. National Institute for Health and Clinical Excellence [Web site]. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor- positive breast cancer. Available at: http://guidance.nice.org. uk/TA112/?c=91496
17. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-35.
18. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005; 16:707-15.
19. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23:6931-40.
20. Abetz L, Barghout V, Thomas S, et al. Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study. Breast Cancer Res Treat 2005; 94(suppl 1):S97 (Abstract 2047).
21. Barghout V, Abetz L, Thomas S, et al. Impact of letrozole on quality of life in post-menopausal women with early breast cancer: does age matter? Breast Cancer Res Treat 2005; 94(suppl 1):S97 (Abstract 2040).
22. Muss HB, Tu D, Ingle JN, et al. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 2006; 100(suppl 1):S23 (Abstract 102).
23. Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006; 12:374-86.
24. Karnon J, Delea T, Johnston SR, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006; 24:237-50.
25. El Ouagari K, Karnon J, Delea T, et al. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 2007; 101:37-49.
26. Ingle J, Tu D, Shepherd L, et al. NCIC CTG MA.17: intent-to-treat analysis (ITT) of randomized patients after a median follow up of 54 months. J Clin Oncol 2006; 24(18 suppl):15s (Abstract 549).
27. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen [published erratum appears in: J Clin Oncol 2008; 26:3659]. J Clin Oncol 2008; 26:1948-55.
28. Goss PE, Ingle JN, Palmer MJ, et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Breast Cancer Res Treat 2005; 94(suppl 1):S10 (Abstract 16).
29. Robert NJ, Goss PE, Ingle JN, et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. J Clin Oncol 2006; 24(18 suppl):15s (Abstract 550).
30. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005; 23:7512-7.
31. Dowsett M, Allred DC on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006; 100(suppl 1):S21 (Abstract 48).
32. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published erratum appears in: N Engl J Med 2006; 354:2200]. N Engl J Med 2005; 353:2747-57.
33. Viale G, Regan M, Dell'Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005; 94(suppl 1):S13 (Abstract 44).
34. Goss PE, Ingle JN, Tu D. NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. Breast Cancer Res Treat 2005; 94(suppl 1):S98 (Abstract 2042).
35. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007; 25:2006-11.
36. Ingle JN, Goss PE, Tu D. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. Breast Cancer Res Treat 2005; 94(suppl 1):S13 (Abstract 17).
37. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006; 99:295-300.
38. Wardley AM. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer 2006; 6(suppl 2):S45-50.
39. Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2006; 20(suppl 1):S5-S13.
40. Mamounas E, Jeong J-H, Wickerham L, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 2006; 100(suppl 1):S22 (Abstract 49).
41. Schmid M, Jakesz R, Samonigg H, et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003; 21:984-90.
42. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005; 23(16 suppl):10S (Abstract 527).
43. Wengström Y, Aapro M, Leto di Priolo S, et al. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. Breast 2007; 16:462-8.
44. Verma S, Pritchard K, Blais N, et al. Canadian clinical practice patterns survey of adjuvant therapies for breast cancer. Breast Cancer Res Treat 2006; 100(suppl 1): S116 (Abstract 2106).
45. Kennecke HF, Ellard S, O'Reilly S, et al. New guidelines for treatment of early hormone-positive breast cancer with tamoxifen and aromatase inhibitors. B C Med J 2006; 48:121-6.
46. Eisen A, Trudeau M, Shelley W, et al. The Role of Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-positive Breast Cancer: Guideline Recommendations. Cancer Care Ontario [Web site]. Available at: http://www.cancercare.on.ca/pdf/pebc1-18s.pdf